Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.
about
Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the hostViral mutation ratesAntibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralizationViral quasispecies evolutionClosing the door on flaviviruses: Entry as a target for antiviral drug designInteraction of Decay-Accelerating Factor with Echovirus 7Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexesMechanisms of viral mutationA single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesisDistribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functionsRelationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses.In vitro selection of human rhinovirus relatively resistant to soluble intercellular adhesion molecule-1Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection.Identification of viral mutants by mass spectrometry.Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives.Toward antiviral strategies that resist viral escapeWIN 52035-dependent human rhinovirus 16: assembly deficiency caused by mutations near the canyon surface.Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase.Virus receptors: implications for pathogenesis and the design of antiviral agents.Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.Long-distance correlations of rhinovirus capsid dynamics contribute to uncoating and antiviral activity.Comparative sensitivity of the echovirus type 25 JV-4 prototype strain and two recent isolates to glutaraldehyde at low concentrationsStructure of a human rhinovirus complexed with its receptor molecule.Viral cell recognition and entry.Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.Potent antiviral agents fail to elicit genetically-stable resistance mutations in either enterovirus 71 or Coxsackievirus A16.WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is presentRole of maturation cleavage in infectivity of picornaviruses: activation of an infectosomeWIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain.Acid-induced structural changes in human rhinovirus 14: possible role in uncoating.Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinoneHuman rhinovirus type 16: mutant V1210A requires capsid-binding drug for assembly of pentamers to form virions during morphogenesis.Spectrum of activity of soluble intercellular adhesion molecule-1 against rhinovirus reference strains and field isolates.The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus.Poliovirus 2C region functions during encapsidation of viral RNA.Discrimination among rhinovirus serotypes for a variant ICAM-1 receptor molecule.Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds.Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.
P2860
Q23925011-EC9D4680-F22C-448F-9958-79D0045ADAA9Q24611162-C4F48A4C-8099-48E2-983C-E91A40ECDB7BQ24654597-3A3A9903-F419-4786-A84B-00A170F32AE5Q27013917-B06CD2AF-0E83-48A6-BC7E-76F3602FCD48Q27487953-98376BAA-536A-4940-9C09-ED3BEECE97BEQ27664791-991A7033-763C-45A5-8266-F7423327053FQ27756974-D2F4A04B-3D24-4373-B4B2-F375642B5559Q28067235-4AB241CA-02DC-46F1-ABFC-041DA277346CQ28804076-D58C2389-76B2-4522-B4D6-C14182C7BEBEQ30193841-D12CC8B8-4BEA-4711-9641-4059F0A2946AQ30447033-D88B4E5B-6D10-4EAA-B220-BB768C200724Q30451273-B12C6574-FB76-4F09-85CE-59453B85AA25Q30451685-E1651879-8BE0-4835-9051-2FD4294C15E3Q32052200-5A40A665-1F56-47E7-B4C5-9C4C04458DE6Q33803519-8C04E6F0-56DB-46FA-A491-B7C67852BEA9Q33979280-B0D44297-F47A-4E43-909A-F2B666F5195BQ34069501-78AC5D88-E995-442B-B828-5825388FC02CQ35012405-F569BC91-6216-4C3D-9A29-73B29BC4D505Q35366667-69852056-A15F-4CCB-87FD-2CF2D2756717Q35828466-6BD79D69-B845-4258-BD15-BE8CE6522C72Q35887229-D79BE371-7F44-4633-8DB1-AA0EF4E3EA8EQ36051232-30C217CD-39CA-400F-8F3C-1D9E1E876375Q36058227-5D8BA2C6-BA0B-49C4-BCAB-3F2D7A563731Q36278326-6CE67A43-A45C-4E56-B9A4-8209DD29A09AQ36364228-4968D6DE-BC3F-4F15-A69D-41E52DCB0218Q36369593-1DCDB102-109D-4E15-9815-CDC3566F3E12Q36642840-99B7F4A9-AE2D-4CDC-A2C5-B7D0898EEABDQ36686327-4420177A-1EB8-4C4D-A367-7480EAA31A60Q36686686-5BE64229-6E7F-4006-AC84-4B59B6C2E4C3Q36798035-190C0962-6F7B-41E0-8E31-70F6FE388A8FQ37272088-DA7B318A-0B17-46FF-B71F-9F60518EBDCBQ37489517-92AA1C08-CAA0-4FC6-8916-663D4DDC6D96Q39752472-0AF3CC62-1C69-4332-9823-556CAB7CAA57Q39867140-383C4F65-3598-4A01-9B53-5C0BFD1C0725Q39870651-58B9A36E-768B-48BA-91A8-D4129CC94285Q39882297-21153C14-C2D9-4189-B10A-8C72F7B8CAFAQ39960136-219AB90B-B945-4B7D-9731-BC0E104583F4Q40163296-F79D7DFA-E900-4EF4-B2A4-5D25A5336345Q40284186-30A2F4C4-44E3-4B9A-A5E7-93BA434AD2F6Q40882626-183B2124-6DB3-49D4-81D3-02594D6A9A36
P2860
Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Genetic and molecular analyses ...... tant to an antiviral compound.
@en
type
label
Genetic and molecular analyses ...... tant to an antiviral compound.
@en
prefLabel
Genetic and molecular analyses ...... tant to an antiviral compound.
@en
P2093
P2860
P1433
P1476
Genetic and molecular analyses ...... tant to an antiviral compound.
@en
P2093
D A Shepard
M A McKinlay
R R Rueckert
P2860
P304
P407
P577
1989-06-01T00:00:00Z